BioCentury | Nov 28, 2020
Product Development

U.K. government advances AZ’s COVID-19 vaccine to regulators

The U.K. has moved into position to become the first country to approve AZD1222 from AstraZeneca and Oxford after the country’s government Friday formally requested that MHRA start a review of the COVID-19 vaccine. The news...
BioCentury | Nov 27, 2020
Deals

With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision

Biogen is paying Sage $1.5 billion up front to gain rights to two late-stage CNS products to bolster the company’s pipeline as it approaches one of the biggest binary decisions in recent industry...
BioCentury | Nov 26, 2020
Product Development

U.S. government spending on Abbott BinaxNOW outstrips other rapid COVID-19 tests: Data Byte

Abbott’s BinaxNOW test has replaced its predecessor as the Trump Administration’s favorite COVID-19 test. A fact sheet released by HHS Tuesday showed the U.S. federal government has spent $760 million on the antigen test from Abbott...
BioCentury | Nov 25, 2020
Product Development

Russia to launch Sputnik V vaccine into global orbit

The Russian government plans to exploit the low manufacturing cost and ease of storing and transporting its Sputnik V vaccine to engage in vaccine diplomacy, filling a gap left by the Trump administration’s America First...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Nov 21, 2020
Product Development

Could an approval of Biogen’s Alzheimer’s therapy still be an option?

For almost any other compound, the nearly unanimous advisory committee vote that Biogen’s Alzheimer’s therapy aducanumab suffered would make its chances of approval vanishingly small. But this mAb...
BioCentury | Nov 21, 2020
Product Development

How Forma is working to show the sickle cell community it’s in for the long haul

As early clinical evidence for its sickle cell disease candidate grows, Forma is prioritizing building relationships with the patient community, with a focus on long-term policy goals and COVID-19 safety...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

A deal with Lilly delivering $135 million up front will allow Precision BioSciences to derive immediate value from the in vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of...
BioCentury | Nov 19, 2020
Management Tracks

CStone’s Yeh joins Abbisko as CFO; plus moves at Ziopharm, Permira, Imara, Inivata, Topas and Arch

Cancer company Abbisko Therapeutics Co. Ltd. hired Richard Yeh as CFO. Yeh was CFO at CStone Pharmaceuticals Co. Ltd. (HKEX:2616). In March, Abbisko raised $70 million in a series C round.  Raffaele Baffa joined Ziopharm...
Items per page:
1 - 10 of 17520